Methadone Clinics in New Mexico: Approvals, Admission, and Take-Home Limits

A methadone clinic in New Mexico needs five things lined up before it can legally dispense a single dose: certification from SAMHSA, a DEA registration specific to narcotic treatment, accreditation from a SAMHSA-approved body, a license from the New Mexico Board of Pharmacy, and approval to operate from the New Mexico Health Care Authority (HCA) under Title 8, Chapter 321 of the New Mexico Administrative Code. Federal treatment standards in 42 CFR Part 8 were substantially revised in late 2024, loosening admission criteria and take-home dose rules while keeping diversion controls and drug testing requirements firmly in place. The rules below reflect what applies now.

The Four Approvals Every Clinic Needs

No single agency regulates methadone clinics. The approvals stack, and losing any one of them collapses the others.

SAMHSA certification is the gateway. Without it, a clinic cannot legally dispense methadone for opioid use disorder treatment. To earn it, an opioid treatment program (OTP) must meet the treatment standards in 42 CFR 8.12, hold current accreditation from a SAMHSA-approved body, and comply with any additional conditions the Secretary sets.¹ Applications use SAMHSA form SMA-162 and must describe organizational structure, responsible personnel, facility addresses, funding sources, and accreditation status. Certification lasts up to three years and can be renewed during the final year. New programs that have applied for accreditation but not yet received it may receive provisional certification for up to one year. Within five days of certifying an OTP, SAMHSA notifies the DEA.

Accreditation comes from a SAMHSA-approved body. If accreditation lapses or a program comes under a formal finding of needed improvement, New Mexico regulations require notification to the state within two business days.² Lose accreditation and you lose certification; lose certification and you cannot dispense.

DEA registration is separate from SAMHSA certification and specific to narcotic treatment. Programs apply on DEA Form 363 online, and the registration must be renewed each year on Form 363a, submitted no more than 60 days before expiration.³ A clinic cannot order, store, or dispense any controlled substance until the DEA assigns a registration number.

The New Mexico Board of Pharmacy issues a separate state license to operate as an OTP. That license is one of the eligibility conditions for HCA approval, discussed next.

How New Mexico State Approval Works

Under NMAC 8.321.10.9, only applicants who already hold SAMHSA certification, DEA registration, a New Mexico Board of Pharmacy OTP license, and accreditation from a SAMHSA-approved body are eligible for HCA approval to operate.⁴ The HCA application is filed on the agency’s designated form and must include detailed operational plans covering patient care, security, and staff qualifications.⁵

The HCA will not approve an entity with a history of noncompliance with state or federal regulations, verified through the DEA, the Board of Pharmacy, the FDA, SAMHSA-approved accreditation bodies, or state licensing agencies in any state where the sponsor operates.

One point trips up buyers of existing clinics: HCA approval is not transferable. If an approved OTP changes ownership, the new owner must apply from scratch as a new program.⁵ A sale does not convey a turnkey operation; it conveys a facility that still needs its own approval.

DEA Security Rules at the Facility

The DEA sets detailed physical security standards for the building itself. Schedule II controlled substances must be stored in a safe, steel cabinet, or vault meeting minimum penetration-resistance standards. Any safe or cabinet weighing under 750 pounds must be bolted or cemented to the floor or wall. If the volume of narcotics warrants it, the storage area must have an alarm transmitting to a central protection company, a police department, or a 24-hour control station run by the program.³

Patients must wait in an area physically separated from the dispensing and storage areas. Only a minimum number of specifically authorized employees can enter the narcotic storage area. Methadone may only be dispensed by a licensed practitioner, registered nurse, licensed practical nurse, or pharmacist working under a licensed practitioner’s direction. Deliveries of narcotic substances can only be accepted by a licensed practitioner or an authorized person designated in writing, and that designee cannot be anyone currently or previously dependent on narcotic drugs.

Who Can Be Admitted as a Patient

The 2024 revisions to 42 CFR Part 8 simplified admission. Qualified personnel must determine, using accepted medical criteria, that the patient meets diagnostic criteria for moderate to severe opioid use disorder, has an active disorder or one in remission, or is at high risk for recurrence or overdose. The patient must voluntarily choose treatment, and all relevant facts about the medication must be clearly explained before informed consent.⁶

The old one-year history of opioid dependency is no longer required. Many clinics still screen as though it is. Under the current rule, what matters is the clinical diagnosis and informed consent, not any set prior duration of use.

Patients under 18 may be admitted, but only with written consent from a parent, legal guardian, or a responsible adult designated by the relevant state authority, unless state law allows the minor to consent on their own. Pregnant patients remain a priority population.

A screening examination must be completed before medication starts. A full in-person physical examination, including lab results, must be completed within 14 calendar days of admission.¹

Through December 31, 2026, HHS and the DEA have extended telemedicine flexibilities that let practitioners prescribe controlled medications for substance use disorder treatment without a prior in-person visit, while permanent telemedicine rules are being finalized.⁷ Prescriptions must still be issued for legitimate medical purposes and comply with federal and state law. For rural areas of New Mexico, where the nearest OTP can be hours away, that window matters.

Take-Home Dose Limits

Take-home rules changed as much as any part of the 2024 revisions. Practitioners are no longer bound to the old rigid schedule that required nine months in treatment before a patient could qualify for weekly clinic visits. Decisions are now guided by overdose prevention, shared decision-making with the patient, and the patient’s individual safety and circumstances.⁸

Federal regulations set outer limits on take-home supply based on time in treatment:

First 14 days: take-home supply beyond clinic closure days is limited to 7 days.
Days 15 through 30: take-home supply is limited to 14 days.
Day 31 and beyond: take-home supply cannot exceed 28 days.

These maximums represent a substantial expansion from pre-2024 rules.¹ Practitioners must still weigh whether the patient has an active substance use disorder, attends regularly, and has no known recent diversion activity before granting take-home privileges.

Drug Testing and the Prescription Monitoring Program

Random drug testing remains a federal requirement. OTPs must use FDA-authorized tests and conduct them at a frequency appropriate to the patient’s clinical situation and stability, with a floor of no fewer than eight random tests per year per patient.¹ That minimum works out to roughly one test every six to seven weeks; programs have discretion to test more often and most do during early treatment.

New Mexico adds a state obligation. Each OTP must participate in the state Prescription Monitoring Program (PMP). All OTP physicians and other authorized prescribers must be registered to use the PMP, and the program must be checked quarterly throughout each patient’s treatment.²

Staffing, Diversion Control, and Patient Records

Every OTP must formally designate a program sponsor and a medical director. The medical director is responsible for the program’s compliance with all applicable federal, state, and local laws.¹

New Mexico does not set a fixed counselor-to-patient ratio. NMAC 8.321.10.18 instead requires each program to adopt written policies for setting counselor caseloads based on the intensity and duration of counseling each patient needs, and NMAC 8.321.10.25 requires the program to employ enough substance abuse counselors to deliver timely access, the services called for in each individualized plan, and unscheduled counseling when needed.⁹ The approach is outcome-based, which gives programs flexibility but means inspectors look at whether patients actually receive the counseling their plans require.

Every program must develop, implement, and comply with a written diversion control plan that assigns specific responsibilities to licensed and administrative staff. The plan must include policies for reporting theft or diversion of medication to regulatory agencies and law enforcement.² Federal rules also require a current diversion control plan as part of quality assurance, reviewed during accreditation surveys.

Patient records receive stronger federal privacy protection than ordinary medical records. Under 42 CFR Part 2, disclosure of patient-identifying information generally requires written consent that includes the patient’s name, a description of the information to be disclosed, the purpose, the patient’s right to revoke, and an expiration date or event.¹⁰ A 2024 final rule aligned Part 2 more closely with HIPAA, but the heightened protections remain. Disclosure without consent is permitted only in narrow circumstances: bona fide medical emergencies where consent cannot be obtained, certain management and financial audits, de-identified public health disclosures, and specific scientific research that meets federal protections. A program cannot condition treatment on a patient’s willingness to consent to disclosure of substance use disorder counseling notes.

What Happens When Clinics Violate the Rules

Enforcement comes from multiple directions, and the penalties stack.

The HCA can impose sanctions on clinics that violate New Mexico’s OTP regulations, including fines, suspension of operations, or permanent revocation of approval. Because the HCA will not approve any entity with a documented history of noncompliance, a revocation in New Mexico can effectively end a sponsor’s ability to operate anywhere in the state.⁵

At the federal level, the DEA can pursue civil monetary penalties against OTPs that violate the Controlled Substances Act. Recordkeeping violations can result in penalties of over $14,000 per violation, and dispensing a controlled substance without a valid prescription can carry penalties exceeding $62,000 per violation. In one enforcement action, a methadone clinic paid a $100,000 civil settlement to resolve recordkeeping allegations and agreed to additional DEA oversight.¹¹ SAMHSA can revoke or suspend certification, which immediately strips a clinic of its legal authority to dispense methadone, and loss of accreditation triggers the same result.

The most severe cases become federal criminal prosecutions. In a New Mexico case, a physician who dispensed methadone and other controlled substances outside the usual course of medical practice faced dispensing charges each carrying a maximum of 20 years in prison and a $1 million fine, along with healthcare fraud charges each carrying up to 10 years and a $250,000 fine; where patient deaths resulted, the dispensing counts carried a mandatory minimum of 20 years and a maximum of life imprisonment.¹²

How Patients Pay

Medicare Part B covers OTP services including methadone, counseling, therapy, intake activities, drug testing, and peer recovery support. Patients enrolled in Medicare who receive services from a Medicare-enrolled OTP pay no copayments, though the Part B deductible still applies for supplies and medications. Coverage includes both in-person and, in certain circumstances, virtual counseling and periodic assessments.¹³

Medicaid coverage of methadone treatment became mandatory under the SUPPORT Act beginning October 1, 2020. The original provision included a sunset date of September 30, 2025; states have been moving to make the benefit permanent in their Medicaid plans, and Congress introduced reauthorization legislation in 2025.¹⁴ The mandatory benefit covers all FDA-approved medications for opioid use disorder, including methadone administered by an OTP, along with associated counseling and behavioral therapy.

1
eCFR. 42 CFR Part 8, Subpart C – Certification and Treatment Standards for Opioid Treatment Programs
2
Cornell Law School. New Mexico Administrative Code 8.321.2.31 – Opioid Treatment Program
3
Drug Enforcement Administration. Narcotic Treatment Program Manual
4
Cornell Law School. New Mexico Administrative Code 8.321.10.9 – Eligibility for Approval to Operate
5
Legal Information Institute. New Mexico Administrative Code 8.321.10.10 – Application for Approval to Operate an Opioid Treatment Program
6
eCFR. 42 CFR 8.12 – Federal Opioid Use Disorder Treatment Standards
7
HHS.gov. HHS and DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026
8
SAMHSA. 42 CFR Part 8 – Expanding Access and Flexibility for Patients
9
New Mexico State Records Center and Archives. New Mexico Administrative Code 8.321.10 NMAC
10
eCFR. 42 CFR Part 2 – Confidentiality of Substance Use Disorder Patient Records
11
United States Department of Justice. Methadone Clinic Pays Civil Penalty to Settle Alleged Controlled Substances Act Violations
12
United States Department of Justice. Pawan Kumar Jain Arraigned on Superseding Indictment Adding New Charges of Unlawfully Dispensing Prescription Drugs and Health Care Fraud Resulting in Deaths
13
Medicare.gov. Opioid Use Disorder Treatment Services
14
Department of Health and Human Services, Centers for Medicare and Medicaid Services. Mandatory Medicaid State Plan Coverage of Medication-Assisted Treatment